Pregnenolone
Trials 19 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03872128 Comparator | Sep 2018 → Nov 2022 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05935761 Comparator | Sep 2026 → Oct 2029 expected | chronic pain syndrome | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06188923 Comparator | Aug 2025 → Jun 2028 expected | mixed anxiety and depressive disorder | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT05671692 Comparator | Sep 2024 → Aug 2026 | traumatic brain injury | Christine Marx, MD | Suspended | No outcome recorded |
| Phase 2 | NCT05781009 Comparator | Jan 2024 → Jul 2028 expected | alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT02826577 Comparator | May 2017 → Dec 2021 | — | University of Chicago | Terminated | No outcome recorded |
| Phase 2 | NCT01336413 Comparator | Oct 2013 → Feb 2016 | traumatic brain injury | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT01898013 Comparator | Sep 2013 → Apr 2017 | — | Durham VA Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00993629 Comparator | Jan → May 2010 | major depressive disorder, post-traumatic stress disorder | US Department of Veterans Affairs | Withdrawn | No outcome recorded |
| Phase 2 | NCT00728728 Comparator | Dec 2009 → Mar 2015 | schizoaffective disorder, schizophrenia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00894842 Comparator | Jun 2009 → Sep 2011 | schizophrenia | National Research Foundation, Singapore | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01409096 Comparator | Mar 2010 → Nov 2011 | bipolar disorder, major depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT00623506 Comparator | Jan 2008 → Aug 2009 | traumatic brain injury | Durham VA Medical Center | Completed | No outcome recorded |
| — | NCT00560781 Comparator | Apr 2006 → Apr 2007 | post-traumatic stress disorder | Durham VA Medical Center | Completed | No outcome recorded |
| — | NCT00560937 Comparator | Jun 2005 → Apr 2006 | schizophrenia | Durham VA Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pregnenolone | “Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.” NCT05894954 ↗34“Pregnenolone 60mg & Pyridoxal Phosphate 20mg & Dydrogesterone 10mg & Impatien balsamina extract 100 mg” NCT04762316 ↗ |
| Known as | PREG | “Pregnenolone (PREG) and dehydroepiandrosterone (DHEA) are reported to have a modulatory effect on neuronal excitability, synaptic plasticity, and response to stress; they are...” PMID 20584515 ↗ Jun 20106“Extensive preclinical and clinical data (from the investigators' group and others) support a novel neurosteroid intervention (pregnenolone/PREG) as a promising new treatment...” NCT06188923 ↗ “Recent preclinical data demonstrate that the neurosteroid pregnenolone (PREG) inhibits THC activation of cannabinoid receptors and decreases symptoms of marijuana intoxication.” NCT02439814 ↗ “The overall purpose of this study is to examine the effect of pregnenolone (PREG) on the acute psychosis-like and cognitive effects of Delta-9-tetrahydrocannabinol (THC).” NCT02576912 ↗ “The NS pregnenolone (PREG) is a logical therapeutic option, since it enhances learning and memory and also increases myelination in rodent models.” NCT01336413 ↗ “Participants will be randomly assigned to 300mg pregnenolone (PREG) treatment b.i.d., or Placebo (PBO).” NCT05781009 ↗ “Pregnenolone (PREG)” NCT03953612 ↗ |
| Known as | pregnenlone | “Pregnenlone (phase 1 and 2)” NCT03505905 ↗ |
| Action | Inhibit | “inhibits THC activation of cannabinoid receptors” NCT02439814 ↗ |
| Modality | Other / unclassified | “Pregnenolone is a "neurosteroid" and possesses intrinsic behavioral and brain effects in animals, affecting the GABA(A) and other receptors.” NCT00174889 ↗ |
| Route | Oral | “one capsule/day” NCT00223197 ↗ |